Alopecia areata (AA) is a disfiguring autoimmune disease mediated by T lymphocytes targeting hair follicles.1 Its incidence increases almost linearly with age, corresponding to a cumulative lifetime incidence of 2.1%.2 Spontaneous regrowth is possible in patients with limited hair loss, whereas <25% of patients suffering of extensive forms of AA [alopecia totalis (AT)/alopecia universalis (AU) or severe multiple AA (MAA)] experience hair regrowth without any therapy.3 We tested azathioprine (AZA) plus methotrexate (MTX) as a rescue treatment in a group of patients with severe AA for whom a first‐line systemic treatment was ineffective (Table 1). All patients underwent to high‐dose pulsed corticosteroids (HDPCT) followed by MTX, as previously described.4 AZA was added to MTX after at least 6 months of total absence, or cosmetically inacceptable, of hair regrowth. Before starting AZA, thiopurine‐methyltransferase (TPMT) genetic testing was performed.

Azathioprine in combination with methotrexate: a therapeutic alternative in severe and recalcitrant forms of alopecia areata?

Mascia P.;Bonamonte D.;
2019

Abstract

Alopecia areata (AA) is a disfiguring autoimmune disease mediated by T lymphocytes targeting hair follicles.1 Its incidence increases almost linearly with age, corresponding to a cumulative lifetime incidence of 2.1%.2 Spontaneous regrowth is possible in patients with limited hair loss, whereas <25% of patients suffering of extensive forms of AA [alopecia totalis (AT)/alopecia universalis (AU) or severe multiple AA (MAA)] experience hair regrowth without any therapy.3 We tested azathioprine (AZA) plus methotrexate (MTX) as a rescue treatment in a group of patients with severe AA for whom a first‐line systemic treatment was ineffective (Table 1). All patients underwent to high‐dose pulsed corticosteroids (HDPCT) followed by MTX, as previously described.4 AZA was added to MTX after at least 6 months of total absence, or cosmetically inacceptable, of hair regrowth. Before starting AZA, thiopurine‐methyltransferase (TPMT) genetic testing was performed.
File in questo prodotto:
File Dimensione Formato  
Mascia_et_al-2019-Journal_of_the_European_Academy_of_Dermatology_and_Venereology.pdf

non disponibili

Tipologia: Documento in Versione Editoriale
Licenza: NON PUBBLICO - Accesso privato/ristretto
Dimensione 280.88 kB
Formato Adobe PDF
280.88 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11586/256372
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 3
social impact